Skip to main content
CSPC Pharmaceutical Group Limited logo

CSPC Pharmaceutical Group Limited — Investor Relations & Filings

Ticker · 1093 ISIN · US12591J1088 LEI · 529900M3XQCW234H8O91 HKEX Manufacturing
Open in API
Filings indexed 1,523 across all filing types
Latest filing 2018-10-09 Transaction in Own Shar…
Country HK Hong Kong
Listing HKEX 1093

About CSPC Pharmaceutical Group Limited

https://www.cspc.com.hk/en/global/home.…

CSPC Pharmaceutical Group Limited is a comprehensive enterprise specializing in the research, development, manufacturing, and sale of pharmaceutical products. The company operates across two main segments: finished drugs and bulk drugs. It emphasizes innovation and new drug development, evidenced by substantial R&D investment, to produce high-quality, effective, and reliable medicines. Its portfolio includes key innovative products such as NBP (soft capsules and injections), Oulaining, and Enxi, which are among its top-selling drugs.

Recent filings

Filing Released Lang Actions
NEXT DAY DISCLOSURE RETURN
Transaction in Own Shares Classification · 100% confidence The document is a Next Day Disclosure Return for a Main Board listed issuer, CSPC Pharmaceutical Group Limited, detailing changes in issued share capital and share buybacks. It includes specific data on share repurchases, dates, prices, and confirmations of compliance with listing rules. The content focuses on reporting share repurchase activity and changes in issued shares, which aligns with announcements related to share buybacks or capital changes. There is no indication of a full financial report, earnings release, or management discussion. The document is regulatory in nature, reporting share capital changes and repurchases as required by stock exchange rules. Therefore, the appropriate classification is 'Transaction in Own Shares' (POS). The document length and detail support this classification with high confidence.
2018-10-09 English
NEXT DAY DISCLOSURE RETURN
Transaction in Own Shares Classification · 95% confidence The document is a Next Day Disclosure Return for a Main Board listed issuer, CSPC Pharmaceutical Group Limited, detailing changes in issued share capital and share buybacks. It includes specific data on share repurchases, dates, prices, and confirmations of compliance with listing rules. The content focuses on reporting share repurchase activity and changes in issued shares, which aligns with announcements related to share buybacks or capital changes. The document is not a full financial report, earnings release, or management discussion, but a regulatory disclosure of share capital changes and repurchases. Therefore, it fits the category of Transaction in Own Shares (POS). The document length is about 5979 characters, sufficient to contain detailed disclosure rather than a brief announcement. Hence, the classification is POS with high confidence.
2018-10-08 English
VOLUNTARY ANNOUNCEMENT - PRODUCT LICENSE AND COMMERCIALIZATION AGREEMENT
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by CSPC Pharmaceutical Group Limited regarding a product license and commercialization agreement with Sinocelltech Limited. It details the terms of the licensing, commercialization responsibilities, payment milestones, and product development status. The document is relatively short (3089 characters) and is an announcement of a business agreement rather than a financial report or regulatory filing. It does not contain financial statements, audit information, management changes, or voting results. It is not a report publication announcement since it does not mention the release or availability of a report. The content fits best under a general regulatory announcement category as it informs the market about a significant business development but does not fall into more specific categories like M&A, capital update, or earnings release. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2018-10-08 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 SEPTEMBER 2018
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Monthly Return of Equity Issuer on Movements in Securities' for the month ended 30/09/2018, submitted to the Hong Kong Exchanges and Clearing Limited. It details movements in authorized and issued share capital, share options, warrants, convertibles, and other share-related transactions. The content focuses on share capital changes and related securities movements rather than financial performance, earnings, or management commentary. It is a regulatory filing reporting monthly share capital movements, typical for compliance with exchange rules. It is not an annual or interim report, earnings release, or management discussion. The document is a regulatory announcement of share capital movements, fitting best under the category of Share Issue/Capital Change (SHA).
2018-10-03 English
VOLUNTARY ANNOUNCEMENT - PRODUCT LICENSE AND COLLABORATION AGREEMENT
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by the board of directors of CSPC Pharmaceutical Group Limited regarding a product license and collaboration agreement with Verastem, Inc. It details the terms of the agreement, including payments and rights related to the oncology drug COPIKTRA. The document is relatively short (3750 characters) and is an announcement of a business agreement rather than a financial report or regulatory filing. It does not contain financial statements, audit information, or management discussion of financial results. It is not a report of voting results, nor a notice of dividend or share transactions. The content fits best under a general regulatory announcement category for miscellaneous filings that do not fit other specific categories. Therefore, the appropriate classification is Regulatory Filings (RNS).
2018-09-26 English
INTERIM REPORT 2018
Interim / Quarterly Report Classification · 95% confidence The document contains detailed financial data including condensed consolidated financial statements, profit and loss statements, statements of financial position, and notes to the financial statements. It also includes management discussion and analysis, financial highlights, and a report on review of condensed consolidated financial statements. The period covered is the six months ended 30 June 2018, indicating it is a half-year report. The length of the document is substantial (15,000 characters), and it contains actual financial data and analysis rather than just an announcement or certification. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). H1 2018
2018-09-11 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.